Emmaus Life Sciences, Inc.
EMMA
$0.01
$0.000.99%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.03% | 19.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.03% | 19.91% | |||
| Cost of Revenue | -4.86% | 64.67% | |||
| Gross Profit | 15.52% | 17.40% | |||
| SG&A Expenses | 67.33% | -36.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.83% | -30.99% | |||
| Operating Income | -65.85% | 418.51% | |||
| Income Before Tax | -29.26% | 13.22% | |||
| Income Tax Expenses | -97.24% | 198.14% | |||
| Earnings from Continuing Operations | 6.02% | -82.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.02% | -82.91% | |||
| EBIT | -65.85% | 418.51% | |||
| EBITDA | -65.02% | 426.09% | |||
| EPS Basic | 7.08% | -82.58% | |||
| Normalized Basic EPS | -258.57% | 61.11% | |||
| EPS Diluted | 7.08% | -82.58% | |||
| Normalized Diluted EPS | -258.57% | 61.11% | |||
| Average Basic Shares Outstanding | 1.08% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.08% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||